Small Pharma Reports Fiscal Second Quarter 2024 Highlights
October 19, 2023 17:10 ET
|
Small Pharma Inc.
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined company’s vision to build an international clinical-stage leader in psychedelic-based...
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
October 12, 2023 17:00 ET
|
Small Pharma Inc.
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma LONDON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small...
Disposition of Common Shares of Small Pharma Inc.
October 02, 2023 16:30 ET
|
Small Pharma Inc.
LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “Company”) between September 25, 2023 and...
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 26, 2023 07:30 ET
|
Small Pharma Inc.
• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI...
Small Pharma Reports Fiscal First Quarter 2024 Highlights
July 27, 2023 17:06 ET
|
Small Pharma Inc.
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in...
Small Pharma Announces SPL028 R&D Strategy Update
July 05, 2023 07:30 ET
|
Small Pharma Inc.
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT...
Small Pharma Announces Management Team Change
July 05, 2023 07:25 ET
|
Small Pharma Inc.
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
June 28, 2023 17:10 ET
|
Small Pharma Inc.
• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical...
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
May 25, 2023 07:50 ET
|
Small Pharma Inc.
LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
May 03, 2023 07:50 ET
|
Small Pharma Inc.
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...